2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Sell
14
MTVA Quote, Financials, Valuation and Earnings
Last price:
$0.65
Seasonality move
:
-25.17%
Day range:
$0.63 - $0.68
52-week range:
$0.63 - $5.30
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.90x
Volume:
390.9K
Avg. volume:
519.7K
1-year change:
-83.99%
Market cap:
$12.7M
Revenue:
--
EPS (TTM):
-$3.08
Analysts' Opinion
-
Consensus RatingMetaVia has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $14.33, MetaVia has an estimated upside of 2104.45% from its current price of $0.65.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $0.65.
Fair Value
-
According to the consensus of 1 analyst, MetaVia has 2104.45% upside to fair value with a price target of $14.33 per share.
MTVA vs. S&P 500
-
Over the past 5 trading days, MetaVia has underperformed the S&P 500 by -21.2% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
MetaVia does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
MetaVia has grown year-over-year revenues for 0 quarters straight. In the most recent quarter MetaVia reported revenues of --.
Earnings Growth
-
MetaVia has grown year-over-year earnings for 0 quarters straight. In the most recent quarter MetaVia reported earnings per share of -$0.36.
Enterprise value:
1.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.07x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$11.1M | -$20.2M | -$25.8M | -$6.9M | -$3.9M | |
| EBITDA | -$11.4M | -$20.2M | -$25.8M | -$6.9M | -$3.9M | |
| Diluted EPS | -$59.74 | -$3.27 | -$3.08 | -$1.32 | -$0.36 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.9M | $13.3M | $31.5M | $16.8M | $12M | |
| Total Assets | $14.2M | $13.5M | $31.5M | $17M | $12.1M | |
| Current Liabilities | $944K | $1.5M | $11M | $6.8M | $7.7M | |
| Total Liabilities | $1M | $1.5M | $11M | $6.9M | $7.7M | |
| Total Equity | $13.2M | $11.9M | $20.5M | $10.1M | $4.4M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.4M | -$14.7M | -$23.1M | -$6.4M | -$4.8M | |
| Cash From Investing | $4K | -$51K | -$3K | -$5K | -- | |
| Cash From Financing | $28.7M | -$80K | $18.3M | -- | -$12K | |
| Free Cash Flow | -$9.4M | -$14.7M | -$23.1M | -$6.4M | -$4.8M | |
MTVA
Sector
Market Cap
$12.7M
$33.4M
Price % of 52-Week High
12.27%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
-83.99%
-40%
Beta (5-Year)
0.206
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.75
200-day SMA
Sell
Level
$2.10
Bollinger Bands (100)
Sell
Level
0.9 - 1.86
Chaikin Money Flow
Buy
Level
2.3M
20-day SMA
Sell
Level
$0.72
Relative Strength Index (RSI14)
Sell
Level
36.76
ADX Line
Sell
Level
12.86
Williams %R
Buy
Level
-92.7542
50-day SMA
Sell
Level
$1.03
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
54.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
Stock Forecast FAQ
In the current month, MTVA has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MTVA average analyst price target in the past 3 months is $14.33.
-
Where Will MetaVia Stock Be In 1 Year?
According to analysts, the consensus estimate is that MetaVia share price will rise to $14.33 per share over the next 12 months.
-
What Do Analysts Say About MetaVia?
Analysts are divided on their view about MetaVia share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that MetaVia is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is MetaVia's Price Target?
The price target for MetaVia over the next 1-year time period is forecast to be $14.33 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MTVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for MetaVia is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MTVA?
You can purchase shares of MetaVia via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase MetaVia shares.
-
What Is The MetaVia Share Price Today?
MetaVia was last trading at $0.65 per share. This represents the most recent stock quote for MetaVia. Yesterday, MetaVia closed at $0.65 per share.
-
How To Buy MetaVia Stock Online?
In order to purchase MetaVia stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
